Publications in collaboration with researchers from Hospital Son Llàtzer (13)

2024

  1. Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial

    The Lancet Haematology

  2. Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study

    Leukemia

2023

  1. Genomics improves risk stratifi cation of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials

    Haematologica, Vol. 108, Núm. 4, pp. 969-980

  2. Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols

    HemaSphere

2021

  1. Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials

    Hematological Oncology, Vol. 39, Núm. 4, pp. 529-538

2016

  1. Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group

    Leukemia Research, Vol. 41, pp. 12-20

  2. Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy

    Leukemia & lymphoma, Vol. 57, Núm. 1, pp. 86-91

2015

  1. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: Results from the Spanish registry

    Leukemia, Vol. 29, Núm. 9, pp. 1875-1881

  2. Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score

    Leukemia Research, Vol. 39, Núm. 1, pp. 52-57

2014

  1. Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes

    Leukemia and Lymphoma, Vol. 55, Núm. 6, pp. 1300-1303

  2. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: Final results of the PETHEMA ALL-AR-03 trial

    Journal of Clinical Oncology, Vol. 32, Núm. 15, pp. 1595-1604

2013

  1. Survival of hematological patients after discharge from the intensive care unit: A prospective observational study

    Critical Care, Vol. 17, Núm. 6

2012

  1. Ventilatory support in critically ill hematology patients with respiratory failure

    Critical Care, Vol. 16, Núm. 4